Researchers develop new, powerful single-cell technique to study environmental effects on DNA
- Single-cell technique to investigate 'epigenetic' changes that influence our development
- New technique will help to reduce the reliance on animal research for this type of study
- Full map of 'epigenetic marks' from individual cells will be critical for understanding early embryonic development
Researchers at the BBSRC-funded Babraham Institute, in collaboration with the Wellcome Trust Sanger Institute Single Cell Genomics Centre, have developed a powerful new single-cell technique to help investigate how the environment affects our development and the traits we inherit from our parents. The technique can be used to map all of the 'epigenetic marks' on the DNA within a single cell. This single-cell approach will boost understanding of embryonic development, could enhance clinical applications like cancer therapy and fertility treatments, and has the potential to reduce the number of mice currently needed for this research.
'Epigenetic marks' are chemical tags or proteins that mark DNA and act as a kind of cellular memory. They do not change the DNA sequence but record a cell's experiences onto the DNA, which allows cells to remember an experience long after it has faded. Placing these tags is part of normal development; they tell genes whether to be switched on or off and so can determine how the cell develops. Different sets of active genes make a skin cell different from a brain cell, for example. However, environmental cues such as diet can also alter where epigenetic tags are laid down on DNA and influence an organism's long-term health.
Dr Gavin Kelsey, from the Babraham Institute, said: "The ability to capture the full map of these epigenetic marks from individual cells will be critical for a full understanding of early embryonic development, cancer progression and aid the development of stem cell therapies.
"Epigenetics research has mostly been reliant on using the mouse as a model organism to study early development. Our new single-cell method gives us an unprecedented ability to study epigenetic processes in human early embryonic development, which has been restricted by the very limited amount of tissue available for analysis."
The research, published in Nature Methods, offers a new single-cell technique capable of analysing DNA methylation – one of the key epigenetic marks – across the whole genome. The method treats the cellular DNA with a chemical called bisulphite. Treated DNA is then amplified and read on high-throughput sequencing machines to show up the location of methylation marks and the genes being affected.
These analyses will help to define how epigenetic changes in individual cells during early development drive cell fate. Current methods observe epigenetic marks in multiple, pooled cells. This can obscure modifications taking place in individual cells at a time in development when each cell has the potential to form in a unique way. The new method has already revealed that many of the methylation marks that differ between individual cells are precisely located in sites that control gene activity.
Dr Gavin Kelsey, said: "Our work provides a proof-of-principle that large-scale, single-cell epigenetic analysis is achievable to help us understand how epigenetic changes control embryonic development. The application of single-cell approaches to epigenetic understanding goes far beyond basic biological research. Future clinical applications could include the analysis of individual cancer cells to provide clinicians with the information to tailor treatments, and improvements in fertility treatment by understanding the potential for epigenetic errors in assisted reproduction technologies."
Prof Wolf Reik, a founder of the Wellcome Trust Sanger Institute Single Cell Genomics Centre, added: "This exciting new method has already given some remarkable insights into how much variation there is in the epigenetic information in embryonic stem cells. This may underlie the enormous plasticity these cells have to develop into many different cell types in the body".
This work was supported by the Biotechnology and Biological Sciences Research Council (BBSRC), Medical Research Council (MRC), the Wellcome Trust, EU Blueprint and EU EpiGeneSys.
Notes to editors
Single-cell genome-wide bisulfite sequencing for assessing epigenetic heterogeneity. Nature Methods.
About the Babraham Institute
The Babraham Institute, which receives strategic funding (£28.8M 2013-2014) from the Biotechnology and Biological Sciences Research Council (BBSRC), undertakes international quality life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. The Institute's research provides greater understanding of the biological events that underlie the normal functions of cells and the implication of failure or abnormalities in these processes. Research focuses on signalling and genome regulation, particularly the interplay between the two and how epigenetic signals can influence important physiological adaptations during the lifespan of an organism. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and healthier ageing. www.babraham.ac.uk
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by Government, and with an annual budget of around £467M (2012-2013), we support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
Tags: The Babraham Institute genetics human health BBSRC press release